Akademik Veri Yönetim Sistemi
EURASIAN JOURNAL OF EMERGENCY MEDICINE, cilt.25, sa.1, ss.166-170, 2026 (ESCI, TRDizin)
Aim: The decongestants are frequently prescribed for symptomatic relief to reduce mucosal congestion. However, even in the absence of overt cardiovascular symptoms, patients may subsequently present with serious acute cardiac events. The present study aims to assess the potential association between recent pseudoephedrine exposure and the occurrence of coronary vasospasm in patients presenting with acute myocardial infarction (AMI) to the emergency department, who reported the use of pseudoephedrine-containing products within the preceding week. Materials and Methods: The study population included patients who presented with chest pain and were diagnosed with AMI [either STelevation myocardial infarction (STEMI) or non-STEMI]. The primary objective was to evaluate the history of pseudoephedrine use within the Results: Among patients with a history of pseudoephedrine use, the 1-month incidence of major adverse cardiac events (MACE) was 13% (n=3), compared to 12.7% (n=21) in those without such a history. When comparing age, diagnosis, and MACE rates between patients with and without pseudoephedrine use, no statistically significant differences were observed. Regarding MACE subtypes, the most frequent event was death, occurring in 7.4% (n=14) of all patients. Heart failure was identified in 2.6% (n=5), while recurrent myocardial infarction was observed in 2.1% (n=4) patients. Conclusion: Our findings suggest a clinically relevant association between recent pseudoephedrine use and acute cardiac events in vulnerable patients. This calls for increased awareness among clinicians, pharmacists, and the general public regarding the possible adverse outcomes associated with pseudoephedrine, even when used short-term or at therapeutic doses.